The Children’s Oncology Group Acute Lymphoblastic Leukemia Molecular Reference Laboratory, directed by Dr. Julie Gastier-Foster, recently received two new awards to facilitate the incorporation of new prognostic markers for risk-stratification in COG trials for patients diagnosed with high-risk ALL. The awards:
Testing Targeted Therapy in Philadelphia Chromosome-like (Ph-like) ALL
St. Baldrick’s Foundation
Funding period: 07/01/13 – 06/3018
Developing Novel Therapies for Pediatric and Young Adult ALL
New York University School of Medicine / Leukemia & Lymphoma Society
Funding Period: 10/01/13 – 09/30/18
The Philadelphia (Ph) chromosome, or BCR-ABL1 fusion, has been associated with poor prognosis for several decades. Recent work within COG has identified a subset of patients with very poor outcome who lack the BCR-ABL1 fusion but have a gene expression profile similar to BCR-ABL1 patients. The translational work at Nationwide Children's Hospital, led by Dr. Shalini Reshmi, will focus on identifying alternative fusion genes in Ph-like patients, who may respond to more targeted therapies.